GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » Notes Receivable

Ulisse Biomed SpA (MIL:UBM) Notes Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ulisse Biomed SpA Notes Receivable?

Ulisse Biomed SpA's Notes Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Ulisse Biomed SpA Notes Receivable Historical Data

The historical data trend for Ulisse Biomed SpA's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ulisse Biomed SpA Notes Receivable Chart

Ulisse Biomed SpA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Ulisse Biomed SpA Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Ulisse Biomed SpA Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Ulisse Biomed SpA Notes Receivable Related Terms

Thank you for viewing the detailed overview of Ulisse Biomed SpA's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ulisse Biomed SpA Business Description

Traded in Other Exchanges
N/A
Address
Area Science Park - SS14 km.163, 5, Basovizza, ITA, 34149
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.

Ulisse Biomed SpA Headlines

No Headlines